Moneycontrol PRO
HomeNewsRanbaxylaboratories

At Moneycontrol, the Results page helps you effectively track corporate announcements and results for various listed companies across both India and abroad. With our Results page, you can keep abreast with an updated, comprehensive view of all the profit/loss statements, company spendings, AGM outcomes, and quarterly and annual results from all these listed companies. Additionally, Moneycontrol also regularly tracks international MNCs listed on NASDAQ and Asian bourses, including popular companies like Apple, Google, Alibaba. Apart from finding solid copies of company results, stock movements consequent to these company results, expectations, and analytical post results copies, you will also find copies and articles detailing the earnings, impact, and all major announcements made to media/exchanges by these companies, so that you do not miss anything. We also provide you with concrete data points to help you spot profitable trades, stock build-ups, and bulk deals. At Moneycontrol, we also cover analysts/investors meetings; scrutinise results and data and BSE/NSE reports or news. The copies are not just full of information and data, but are also adequately supplemented with expert views, investor opinions, extensive interviews, videos, and a huge variety of explainers, analyses, and informative slideshows to help you gauge the market and make investment decisions in the best possible manner. More

Jump to
  • Ranbaxy Sept qtr PAT seen at Rs 291cr: Angel

    Ranbaxy Sept qtr PAT seen at Rs 291cr: Angel

    Angel Broking has come out with its earning estimates on pharma sector for the quarter ended September 2011. According to the research firm, Ranbaxy September quarter net sales are expected to go up by 9.1% at Rs 2,054 crore, year-on-year, (YoY) basis.

  • Apr-June qtr: Pharma cos to see healthy sales, sick margins

    Apr-June qtr: Pharma cos to see healthy sales, sick margins

    Pharmaceutical sector has been in the pink of health this year with most stocks outperforming the broader market since the beginning of April. However, there could be some suffering ahead.

  • Ranbaxy Jun qtr PAT seen at Rs 110cr: KRChoksey

    Ranbaxy Jun qtr PAT seen at Rs 110cr: KRChoksey

    KRChoksey has come out with its earning estimates on pharma sector for the quarter ended June 2011. According to the research firm, Ranbaxy June quarter sales are expected to go down by 8% at Rs 1980 crore, year-on-year, (YoY) basis.

  • Ranbaxy Labs Q1CY11 PAT seen down 83% at Rs 167cr

    Ranbaxy Labs Q1CY11 PAT seen down 83% at Rs 167cr

    Ranbaxy Laboratories is to announce its first quarter CY11 results. According to CNBC-TV18's estimates, it revenues are seen down 23% to Rs 2126 crore versus Rs 2767 crore, year-on-year, YoY, basis.

  • Ranbaxy Labs Mar qtr PAT seen up at Rs 92.7 cr: MOST

    Ranbaxy Labs Mar qtr PAT seen up at Rs 92.7 cr: MOST

    Motilal Oswal has come out with its earning estimates on Pharmaceuticals sector for the quarter ended March 2011. According to the research firm, Ranbaxy Labs March quarter sales are expected to go up by 13% at Rs 1842 crore, year-on-year, (YoY) basis.

  • Ranbaxy March qtr PAT seen at Rs 267cr: KRChoksey

    Ranbaxy March qtr PAT seen at Rs 267cr: KRChoksey

    KRChoksey has come out with its earning estimates on pharma sector for the quarter ended March 2011. According to the research firm, Ranbaxy Laboratories March quarter sales are expected to go down by 17% at Rs 2,310 crore, year-on-year, (YoY) basis.

  • Ranbaxy Labs Q4 PAT seen up 23% at Rs 323 cr

    Ranbaxy Labs Q4 PAT seen up 23% at Rs 323 cr

    Pharma major Ranbaxy Labs is set to announce its results for the quarter ended December 2010. According to CNBC-TV18 estimates, its profit after tax (PAT) is expected to go up by 23% to Rs 323 crore in Q4CY10 as against Rs 262 crore in same quarter the previous year.

  • Ranbaxy Lab Dec qtr PAT seen up 22% at Rs 312cr: Angel

    Ranbaxy Lab Dec qtr PAT seen up 22% at Rs 312cr: Angel

    Angel Broking has come out with its earning estimates on the pharmaceutical sector for the quarter ended December 2010. According to the research firm, Ranbaxy Lab December quarter net sales are expected to go up by 0.9% to Rs 2,266 crore, Year-on-Year, (Y-o-Y) basis.

  • Ranbaxy Labs Dec qtr PAT seen up 2.4% at Rs 261.8cr: Karvy

    Ranbaxy Labs Dec qtr PAT seen up 2.4% at Rs 261.8cr: Karvy

    Karvy Stock Broking has come out with its earning estimates on pharma sector for the quarter ended December 2010. According to the research firm, Ranbaxy Laboratories December quarter sales are expected to go down by 2.5% at Rs 2197.7 crore, Year-on-Year, (YoY) basis.

  • Ranbaxy Dec qtr PAT seen up 193% at Rs 319.9cr: Emkay

    Ranbaxy Dec qtr PAT seen up 193% at Rs 319.9cr: Emkay

    Emkay Global Financial Services has come out with its earning estimates on pharma sector for the quarter ended December 2010. According to the research firm, Ranbaxy December quarter sales are expected to go up by 4.7% to Rs 2361.3 crore, Year-on-Year, (Y-o-Y) basis.

  • Ranbaxy Lab Dec qtr PAT seen up 825% at Rs 1078cr:KRChoksey

    Ranbaxy Lab Dec qtr PAT seen up 825% at Rs 1078cr:KRChoksey

    KRChoksey has come out with its earning estimates on pharma sector for the quarter ended December 2010. According to the research firm, Ranbaxy Laboratories December quarter sales are expected to go up by 14% to Rs 2141 crore, Year-on-Year, (Y-o-Y) basis.

Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347